Psychedelic

PRO-LAD

Also called N-Propylnorlsd

Original Wikipedia articleen.wikipedia.org/wiki/PRO-LAD revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Common dose · Oral100–200 µg PW

Onset30–45 minutes PW

Total6–8 hours PW

Dosage

Light

Common

Strong

Heavy

02050100200350µg

Oral bands as drawn from PsychonautWiki's ranges below. The table is the source of truth.

When sources disagree, both rows are shown as published. Nothing is averaged or merged.

Oral

Source	Threshold	Light	Common	Strong	Heavy
PsychonautWiki	20 µg PW	50–100 µg PW	100–200 µg PW	200–350 µg PW	350 µg+ PW
TripSit	–	50–100 ug TS	100–150 ug TS	150–200 ug. TS	–

TripSit dose text

TripSit's factsheet also states its doses as text.

Light: 50-100ug Common: 100-150ug Strong: 150-200ug. TS

What dose are you on? (self-reported, unverified)

Read this first. These numbers come from anonymous visitors typing in a box. Nobody checks them. People misjudge, mistype, troll, or take untested products of unknown strength. They are not a dose guide and never override the sourced table above. They exist only so the sourced ranges can be compared with what people say they take. If you are deciding what to take, use the sourced table, start low, and read the risks section.

Running self-reports

No reports yet.

Reports are anonymous, one per browser per day per route. Counts under 20 are shown but marked as too few to mean anything. Until accounts launch, reports stay in this browser only.

Duration

Route · source	Onset	Come-up	Peak	Offset	Total	After-effects
Oral · PsychonautWiki	30–45 minutes PW	–	–	–	6–8 hours PW	–

TripSit factsheet

Onset: 30-45 minutes TS
Duration: 6-10 hours TS

Mixing

Acute combinations: what happens when these are taken close together. Entries backed by a medical journal or agency are listed first.

Backed by medical journals

Awaiting sourcePeer-reviewed reports on acute combinations, from PubMed and the journals the harm reduction sites cite.

PsychonautWiki also lists dangerous combinations shared across a whole group (psychedelics) in a table this page does not copy. Read that list on PsychonautWiki.

Risks and toxicity

The toxicity and long-term health effects of recreational PRO-LAD do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because PRO-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried PRO-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. PW

It is strongly recommended that one use harm reduction practices when using this substance. PW

Dependence and abuse potential

While no formal studies have been conducted, PRO-LAD is likely not habit-forming and it is reasonable to speculate that the desire to use it can actually decrease with repeated administratino. As with most psychedelics, it likely possesses what is considered an intrinsic, self-regulating aspect to it. PW

Tolerance to the effects of PRO-LAD is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). PRO-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of PRO-LAD all psychedelics will have a reduced effect. PW

Testing

Awaiting sourceReagent reactions and test kit guidance from a harm reduction testing service.

Effects

Awaiting sourceSubjective and physical effects from PsychonautWiki or TripSit.

Shulgin notes

These figures come from the Shulgins' own small trials, published decades ago. They are history, not a dosing guide: they were never checked the way a harm reduction dose table is, and batches, purity and people differ.

Book: TiHKAL (1997), entry #51
Dose listed: 100–200 μg orally WP
Duration listed: 6–8 hours WP

Read entry #51 in Erowid's online library

From PiHKAL and TiHKAL by Alexander and Ann Shulgin, as tabulated in Wikipedia's articles on the books (CC BY-SA 4.0). The books' text belongs to the Shulgins, so only the listed figures and a link are given here. Synthesis details are never shown on this site.

Overview

N-Propylnorlysergic acid N,N-diethylamide (also known as 6-Propyl-6-nor-lysergic acid diethylamide, N-PropylnorLSD or simply PRO-LAD) is a novel psychedelic substance of the lysergamide class. It is a structural analog of LSD and is part of a series of LSD analogs which includes AL-LAD and ETH-LAD.[1] PW

A very rare lysergamide that is slightly less potent than LSD, yet with a shorter duration of action. TS

PRO-LAD, or PROLAD, also known as 6-propyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is taken orally.[2][3] WP

History

PRO-LAD was first described in the scientific literature by Tetsukichi Niwaguchi and colleagues in 1976. Subsequently, it was studied and described by Andrew J. Hoffman and David E. Nichols in 1985. The hallucinogenic effects of PRO-LAD in humans were first described by Nichols in a literature review via personal communication with Alexander Shulgin in 1986. The drug was later described in greater detail by Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). PRO-LAD is said to have been encountered as a novel designer drug by 2015.[2][4–8] WP

Legal status

Austria: PRO-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. PW⚠ PsychonautWiki itself has flagged this text: citation needed.
Germany: PRO-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[9][10][11] PW
Latvia: PRO-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.[12] PW
Switzerland: On December 1, 2015, Switzerland added PRO-LAD to the list of controlled substances. It is a controlled substance specifically named under Verzeichnis E.[13] PW
United Kingdom: As of January 7, 2015, PRO-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.[14] PW

Canada

PRO-LAD is not a controlled substance in Canada as of 2025.[15] WP

Switzerland

PRO-LAD is illegal in Switzerland as of December 2015.[13] WP

United kingdom

On June 10, 2014, the United Kingdom Advisory Council on the Misuse of Drugs (ACMD) recommended that PRO-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.[16] WP

United states

PRO-LAD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.[17] WP

Pharmacology

Pharmacodynamics

PRO-LAD shows affinity for serotonin receptors, including for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. It acts as a partial agonist of the serotonin 5-HT2A receptor similarly to LSD.[18–21] WP

The drug fully substitutes for LSD in rodent drug discrimination tests and with about the same or slightly greater potency than LSD itself. On the other hand, it was about 2- to 3-fold less potent than ETH-LAD or AL-LAD.[3][5][18][20][21] WP

Chemistry

Formula: C22H29N3O PC
CAS number: 65527-63-1 PC
Molar mass (g/mol): 351.5 PC
IUPAC name (computed by PubChem): (6aR,9R)-N,N-diethyl-7-propyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide PC
SMILES: CCCN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)N(CC)CC PC
InChIKey: HZKYLVLOBYNKKM-OXQOHEQNSA-N PC
PubChem CID: 44457803

User reports

Erowid erowid.org

Listings

Awaiting sourceExperience Vault listing and report categories.

Bluelight bluelight.org

Listings

Awaiting sourceTrip report threads and this substance's discussion forum.

Reddit reddit.com

Listings

Awaiting sourceTrip report posts and the relevant subreddits.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

References

Journal / agency COMPOUND SUMMARY: Pro-lad
Harm reduction site CiteTiHKAL
Other Nichols DE, Oberlender R, McKenna DJ. Biochemistry and Physiology of Substance Abuse. 1991
Journal / agency Niwaguchi T, Nakahara Y, Ishii H. Lysergic Acid Diethylamideおよび関連化合物に関する研究(第4報)Norlysergic Acidの各種Amide誘導体ならびに関連化合物の合成. Yakugaku Zasshi. 1976. doi:10.1248/yakushi1947.96.5_673 · PMID 987200
Journal / agency Hoffman AJ, Nichols DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry. September 1985. doi:10.1021/jm00147a022 · PMID 4032428
Journal / agency Nichols DE. Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacol Biochem Behav. February 1986. doi:10.1016/0091-3057(86)90362-x · PMID 3952123
Journal / agency Schifano F, Papanti GD, Orsolini L, Corkery JM. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Expert Rev Clin Pharmacol. July 2016. doi:10.1586/17512433.2016.1167597 · PMID 26985969
Journal / agency Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P. A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies. Analyst. January 2025. doi:10.1039/d4an01361a · PMID 39636448
Other Anlage NpSG
Other Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes
Other § 4 NpSG
Other Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
Other Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien
Other Advisory Council on the Misuse of Drugs (ACMD). Update of the generic definition for tryptamines. June 10, 2014
Other Controlled Drugs and Substances Act
Other ACMD. Update of the Generic Definition for Tryptamines. 10 June 2014
Other Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026). January 2026
Journal / agency Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE. Lysergamides revisited. NIDA Research Monograph. 1994. PMID 8742794
Other McCorvy JD. Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics. 16 January 2013
Other Hoffman AJ. Synthesis and pharmacological evaluation of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. August 1987
Journal / agency Nichols DE. Psychedelics. Pharmacol Rev. April 2016. doi:10.1124/pr.115.011478 · PMID 26841800 · PMC4813425

Text and values on this page are quoted from PsychonautWiki (CC BY-SA 4.0), Wikipedia (CC BY-SA 4.0), TripSit factsheets, PubChem (public domain). Each value links to the exact revision it came from.